The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world

@article{Bingham2021TheUG,
  title={The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world},
  author={Kate Bingham},
  journal={Lancet (London, England)},
  year={2021},
  volume={397},
  pages={68 - 70}
}
  • K. Bingham
  • Published 27 October 2020
  • Engineering
  • Lancet (London, England)
View on Elsevier
thelancet.com
24 Citations
Background Citations
6

24 Citations

Citation Type

Citation Type

Institutional Responsibility is Prior to Personal Responsibility in a Pandemic
Taking these sentiments together, it was hard to avoid the conclusion that the government took responsibility only for doing everything right. Such an admission of responsibility, accommodating no…
References
  • Power, Policy and the Pandemic
  • 2022
Vaccine nationalism will persist: global public goods need effective engagement of global citizens
Covid-19 presents a unique opportunity to transform democratic engagement in the governance of global public goods. In this paper, I describe a global public goods framework and how it relates to…
What Matters for Depression and Anxiety During the COVID-19 Quarantine?: Results of an Online Cross-Sectional Survey in Seoul, South Korea
TLDR
The need to develop precautionary measures to prevent depression and anxiety among people undergoing COVID-19 quarantine is highlighted, in particular, individuals with depression prior to quarantine should be carefully monitored during the quarantine.
A continuation of a timeline of ivermectin-related events in the COVID-19 pandemic
TLDR
There was a noticeable centralization of power, with the pandemic response largely directed by a few public-private partnerships working on commercializable technologies.
A national survey of potential acceptance of COVID-19 vaccines in healthcare workers in Egypt
TLDR
Vaccine hesitancy is not uncommon in healthcare employees in Egypt and this may be an alarming barrier of vaccine acceptance in the rest of population, so there is an urgent need to start campaigns to increase the awareness of the vaccine importance.
A step backwards in the fight against global vaccine inequities
COVID-19 Vaccine Prioritisation for Medical Students: The Forgotten Cohort?
COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea
TLDR
This study revealed that, in order to maintain the current vaccine priority policy, it is important to ensure that the reproductive number does not exceed the threshold by concurrently implementing nonpharmaceutical interventions.
Explaining divergent National Responses to Covid-19: An Enhanced State Capacity Framework
...
1
2
3
...

References

SHOWING 1-7 OF 7 REFERENCES
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
TLDR
The most frequent local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, headache and myalgia, indicative of a Th1-skewed phenotype in both cohorts.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
WHO Coronavirus Disease (COVID-19) Dashboard
  • C. E.
  • Psychology, Medicine
  • 2020
Globally, as of 10:47am CEST, 28 May 2020, there have been 5,556,679 confirmed cases of COVID-19, including 351,866 deaths, reported to WHO
2 Centers for Disease Control and Prevention. Provisional death counts for coronavirus disease 2019 (COVID19): daily updates of totals by week and state
Coronavirus vaccine studies volunteers dashboard
  • National Health Service Digital
JCVI: updated interim advice on priority groups for COVID19 vaccination